Impact of SARS-CoV-2 Infection on Humoral and Cellular Immunity in a Cohort of Vaccinated Solid Organ Transplant Recipients
Ayala-Borges, Bernardo (Hospital Clínic i Provincial de Barcelona)
Escobedo, Miguel (Hospital Clínic i Provincial de Barcelona)
Egri, Natalia (Hospital Clínic i Provincial de Barcelona)
Herrera, Sabina (Instituto de Salud Carlos III)
Crespo, Marta (Institut Hospital del Mar d'Investigacions Mèdiques)
Mirabet Pérez, Sonia (Institut d'Investigació Biomèdica Sant Pau)
Arias Cabrales, Carlos E. (Institut Hospital del Mar d'Investigacions Mèdiques)
Vilella, Anna (Hospital Clínic i Provincial de Barcelona)
Palou, Eduard (Hospital Clínic i Provincial de Barcelona)
Mosquera, María M. (Hospital Clínic i Provincial de Barcelona)
Pascal, Mariona (Universitat de Barcelona)
Colmenero, Jordi (Universitat de Barcelona)
Farrero, Marta (Hospital Clínic i Provincial de Barcelona)
Bodro, Marta (Hospital Clínic i Provincial de Barcelona)
Universitat Autònoma de Barcelona

Fecha:	2023
Resumen:	The aim of the present study was to determine humoral and T-cell responses after four doses of mRNA-1273 vaccine in solid organ transplant (SOT) recipients, and to study predictors of immunogenicity, including the role of previous SARS-CoV-2 infection in immunity. Secondarily, safety was also assessed. Liver, heart, and kidney transplant recipients eligible for SARS-CoV-2 vaccination from three different institutions in Barcelona, Spain were included. IgM/IgG antibodies and T cell ELISpot against the S protein four weeks after receiving four consecutive booster doses of the vaccine were analyzed. One hundred and forty-three SOT recipients were included (41% liver, 38% heart, and 21% kidney). The median time from transplantation to vaccination was 6. 6 years (SD 7. 4). In total, 93% of the patients developed SARS-CoV-2 IgM/IgG antibodies and 94% S-ELISpot positivity. In total, 97% of recipients developed either humoral or cellular response (100% of liver recipients, 95% of heart recipients, and 88% of kidney recipients). Hypogammaglobulinemia was associated with the absence of SARS-CoV-2 IgG/IgM antibodies and S-ELISpot reactivity after vaccination, whereas past symptomatic SARS-CoV-2 infection was associated with SARS-CoV-2 IgG/IgM antibodies and S-ELISpot reactivity. Local and systemic side effects were generally mild or moderate, and no recipients experienced the development of de novo DSA or graft dysfunction following vaccination.
Ayudas:	Instituto de Salud Carlos III PI22/01234
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	COVID-19 ; Cellular ; Humoral immunity ; Immunity ; Solid organ transplant recipients ; Vaccination
Publicado en:	Vaccines (Basel), Vol. 11 Núm. 12 (december 2023) , p. 1845, ISSN 2076-393X

DOI: 10.3390/vaccines11121845
PMID: 38140248

12 p, 840.2 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados